EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Arbutus Biopharma's enterprise value is $364.04 Mil.
Arbutus Biopharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $18.14 Mil. Therefore, Arbutus Biopharma's EV-to-Revenue for today is 20.07.
The historical rank and industry rank for Arbutus Biopharma's EV-to-Revenue or its related term are showing as below:
ABUS'
s EV-to-Revenue Range Over the Past 10 Years
Min: -1.43 Med: 19.52 Max: 144.06
Current: 20.07
During the past 13 years, the highest EV-to-Revenue of Arbutus Biopharma was 144.06. The lowest was -1.43. And the median was 19.52.
ABUS's EV-to-Revenue is ranked worse than 67.57% of 1036
companies
in the Biotechnology industry
Industry Median: 7.98
vs ABUS: 20.07
The historical data trend for Arbutus Biopharma's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Arbutus Biopharma's EV-to-Revenue
For the Biotechnology subindustry, Arbutus Biopharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arbutus Biopharma's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Arbutus Biopharma's EV-to-Revenue falls into.
Arbutus Biopharma's current Enterprise Value is $364.04 Mil.
Arbutus Biopharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arbutus Biopharma's share price for today is $2.71.
Arbutus Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.11.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arbutus Biopharma EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Arbutus Biopharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Arbutus Biopharma (Arbutus Biopharma) Business Description
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ABUS has been successfully added to your 